Summit Therapeutics Share Price (SUMM)

119.50 -3.50 (-2.85%) delayed: 3:11PM GMT
Bid price 116.00 Open price 116.00
Ask price 123.00 Prev close 119.50
High price 119.00 Spread 5.69%
Low price 115.36 Volume 18,948

Register now for FREE live Summit Therapeutics share prices, Summit Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Summit Therapeutics Level 2 Data, indepth research tools and investor commentary for Summit Therapeutics (SUMM) and other London Stock Exchange equities.

Summit Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Summit Therapeutics share price charts

Summit Therapeutics Share Price Information

Name Summit Therapeutics Epic SUMM
Sector Pharmaceuticals & Biotechnology ISIN GB00BN40HZ01
Activites Summit Therapeutics plc (formerly Summit Corporation plc, formerly VASTox plc) is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit's goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Index n/a

Summit Therapeutics Key Numbers

Latest Share Price (p) 119.50 Net Gearing (%) -35.24
Market Capitalisation (£m) 70.76 Gross Gearing (%) 22.84
Shares in issue (m) 61.00 Debt Ratio 4.25
P/E Ratio -4.00 Debt-to-Equity Ratio 0.15
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.30
Dividend Yield (%) 0.00 Price to book value 4.73
Dividend cover (x) 0.00 ROCE (%) -81.00
Earning per share (p) -29.00 EPS Growth (%) -1,846.31
52 week high / low 185.00 / 112.50 DPS Growth (%) n/a

Summit Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
30/07/2014 BUY Glyn Edwards CEO 30,000
26/07/2013 PLAC Glyn Edwards CEO 600,000
26/07/2013 PLAC Dr Frank Armstrong CH 50,000
26/07/2013 PLAC Barry Price NED 500,000
26/07/2013 PLAC Jim Mellon RES 20,000,000

More Summit Therapeutics Director Deals >>

Summit Therapeutics Company News

12:50 03/02/2016

Summit CEO to present at conference in New York

Summit Therapeutics has confirmed that Mr Glyn Edwards, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference, 9 February 2016 in New York City. At 12:50pm: (LON:SUMM) Summit Therapeutics PLC share price was -1.5p at 121.5p Story provided by...

12:00 03/02/2016

Summit Therapeutics to Present at BIO CEO & Inv...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics to Present at BIO CEO & Investor Conference Summit Therapeutics plc ("Summit" or the "Company") SUMMIT...

12:09 21/01/2016

Summit gets UK approval for drug trial

Summit Therapeutics has announced that it has received approval from the UK Medicines and Healthcare products Regulatory Agency and the Research Ethics Committee to initiate PhaseOut DMD, a Phase 2 proof of concept clinical trial of SMT C1100 in patients with DMD. SMT C1100 is an orally...

More Summit Therapeutics Company News >>

Register now for FREE Summit Therapeutics company news

Summit Therapeutics Share Price Discussions

4 months ago

Summit Corporation PLC (SUMM) Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease...

more than 1 year ago

Summer Bonanza is upon us.......... (SUMM)

OK folks it's mid March and spring is upon us. Time to start looking ahead, the mkts have had a bit of a setback, is this the healthy correction that's been spoken about for so long or is it a buying opportunity on the road to new highs? Who knows, not me for sure, if I did I'd tell ya'll...

Register now for FREE Summit Therapeutics share price discussions